Other Information
−Removed: No “Rule 10b5-1 plans” or “non-Rule 10b5-1 trading arrangements”, as each term is defined in Item 408(a) of Regulation S-K, were adopted, modified, or terminated by officers or directors of the Company.
+Added: During our fiscal quarter ended March 31, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
See Exhibit Index.
4 unchanged sentences
(incorporated by reference to Exhibit 3.2 to the Form 8-K filed on September 16, 2024, File No.
−Removed: Zenas BioPharma, Inc.
−Removed: 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.6 the Form S-8 filed on September 16, 2024, File No.
−Removed: Zenas BioPharma, Inc.
−Removed: 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.7 the Form S-8 filed on September 16, 2024, File No.
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
15 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
−Removed: November 12, 2024
ZENAS BIOPHARMA, INC.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.